This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...
Smithsonian Magazine on MSN
Horseshoe Crab Blood Has Long Helped Us Make Safe Medicines. Now, Alternatives That Spare the Ancient Creatures Might Be Breaking Through
An enzyme in the blue blood has been key to testing vaccines since the 1980s, raising concerns for the crabs’ population. But ...
Visit to Klang manufacturing facility held in conjunction with 14th SMIIC Technical Committee Week 2025 in Kuala Lumpur -- ...
Thermo Fisher Scientific invests ₹160 crore to expand its Bengaluru R&D centre, enhancing research in infectious diseases and ...
Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald ...
Preclinical studies have shown CPV-104 to be functionally equivalent to endogenous human Factor H, with the ability to normalize serum C3 levels and promote clearance of pathogenic complement deposits ...
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies ...
Ferring Pharmaceuticals Presents Two New Analyses of Pivotal Trial Data for Follitropin Delta (FE 999049) at ASRM 2025 ...
EMA committee issues positive opinion to support the approval of GSK’s recombinant zoster vaccine, Shingrix in a prefilled syringe: London, UK Wednesday, October 22, 2025, 16:00 ...
The EVERY Co has urged a court in Wisconsin to toss a lawsuit from Onego Bio seeking to invalidate one of EVERY's patents.
13d
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback